10-Q: Vystar Corporation Reports Q1 2025 Results: Revenue Declines Amid Ongoing Financial Challenges

Sentiment:

Quarterly Report 15 May 2025 6:19 AM

Vystar Corporation's Q1 2025 results reveal a significant revenue decrease and continued net losses, raising concerns about the company's ability to continue as a going concern.

Capital raiseThe company plans to finance future operations through stock issuances to new and existing shareholders.The company received $145,000 in stock subscriptions during the three months ended March 31, 2025.The company is offering common stock subscription agreements related to the 2021 shareholder convertible notes conversion.

Worse than expectedThe company's revenue decreased significantly compared to the same period last year.The net loss increased, indicating worsening financial performance.The company's cash position remains weak, and there is substantial doubt about its ability to continue as a going concern.

Summary

Vystar Corporation reported a net loss of $538,282 for the three months ended March 31, 2025, compared to a net loss of $374,718 for the same period in 2024.
Revenue decreased by 66.3% to $12,657 in Q1 2025 from $37,607 in Q1 2024, primarily due to reduced sales to a former major customer.
The company's operating expenses decreased slightly by 4.2% to $342,277, driven by the temporary suspension of consulting fees.
Other expenses significantly increased to $200,312 due to accrued interest, amortization of debt discount on related party debt, and loss on settlement of debt.
As of March 31, 2025, Vystar had cash of $43,250 and a working capital deficit of approximately $6 million, with an accumulated deficit of $60.4 million.
The company's ability to continue as a going concern is dependent on securing additional financing and achieving adequate revenue levels.
Management plans to finance future operations through increased revenue from RxAir air purification units, Vytex license fees, and stock issuances.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to declining revenue, increasing net losses, and concerns about the company's ability to continue as a going concern. The presence of material weaknesses in internal control further contributes to the negative sentiment.

Positives

Operating expenses decreased slightly, indicating some cost control measures.
The company is exploring merger and acquisition opportunities, which could provide a path to growth.
Vystar is actively working on improving internal controls with an outside CPA firm and internal resources.

Negatives

Significant decrease in revenue indicates challenges in sales and marketing.
Increased net loss raises concerns about the company's profitability.
High level of debt and related expenses negatively impacts financial performance.
Substantial doubt exists regarding the company's ability to continue as a going concern.
Material weaknesses in internal control over financial reporting were identified.

Risks

The company's ability to secure additional financing is uncertain.
Failure to achieve projected revenue levels could lead to curtailment of operations or bankruptcy.
Market acceptance of the company's products and services is not guaranteed.
Competition and technological developments could negatively impact the company's prospects.
The ongoing legal proceedings with EMA Financial could result in significant costs.

Future Outlook

The company plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees, and stock issuances to new and existing shareholders. The Company is also exploring merger and acquisition opportunities.

Industry Context

The company operates in the air purification and latex industries, which are subject to market trends, competition, and regulatory changes. The report mentions the impact of the COVID-19 pandemic on the natural rubber supply chain and the company's efforts to adapt to the new economic circumstances.

Comparison to Industry Standards

The document does not provide specific comparisons to industry standards or competitors.
Without additional information, it is difficult to assess Vystar's performance relative to industry benchmarks.
A comprehensive industry analysis would require comparing Vystar's financial metrics to those of similar companies in the air purification and latex sectors.

Legal Proceedings

The Company is subject to legal proceedings and claims that have not been fully resolved and have arisen in the ordinary course of business.
Both parties filed their final briefs in March 2025 with the Second Circuit Court of Appeals in the EMA Financial lawsuit, and we await the decision of the Court.

Related Party Transactions

The company has entered into employment and consulting agreements with certain of our officers, employees, and affiliates.
Blue Oar Consulting, Inc., owned by the sister of the company's CEO, provides business consulting services to the company.
Dr. Bryan Stone, one of the company's directors, receives a commission for RxAir units sold to a specific customer.

Stakeholder Impact

Shareholders face the risk of further dilution through stock issuances.
Employees' job security is uncertain due to the company's financial challenges.
Customers may be concerned about the company's ability to provide ongoing support and service.
Suppliers may face increased credit risk due to the company's financial instability.
Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

The company will be reviewing its pricing and sales strategies in the second and third quarter of 2025.
Management expects to strengthen internal control during 2025 by developing stronger business and financial processes for accounting for transactions.
The company awaits the decision of the Second Circuit Court of Appeals in the EMA Financial lawsuit.

Key Dates

Date	Description
2004-12-31	Vystar adopted a stock option plan.
2009-04-01	Vystar's Board of Directors authorized an increase in the number of shares to be issued under the stock option plan.
2013-05-02	The Company began a private placement offering to sell shares of the Company's Series A Cumulative Convertible Preferred Stock.
2018-12-31	Vystar issued shareholder contingently convertible notes payable.
2019-05-01	The Company acquired the assets of Fluid Energy Conversion Inc. (FEC).
2019-07-18	Bernard Rotman was issued a related party note payable in connection with the acquisition of 58% of Rotmans.
2021-08-17	The Company issued a contingently convertible promissory note to Jamie Rotman.
2022-04-11	The Company amended its Articles of Incorporation to add the terms of a 10% Series B Cumulative Convertible Preferred Stock.
2022-07-08	The Company amended its Articles of Incorporation to add the terms of a 10% Series C Cumulative Convertible Preferred Stock.
2022-12-14	Rotmans closed its showroom.
2023-11-27	The Court issued its order resolving the case in Vystar's favor in the EMA Financial lawsuit.
2024-06-01	The Company entered into a term convertible promissory note with Blue Oar Consulting, Inc.
2024-07-22	The Company entered into an Employment Agreement with Jamie Rotman.
2025-01-01	The Company offered two conversion options to the holders of the 2021 contingently convertible promissory notes.
2025-03-31	End of the quarterly period.
2025-05-15	Date of the report filing.

Keywords

Vystar, RxAir, Vytex, Financial Results, Q1 2025, Net Loss, Revenue, Going Concern, Air Purification, Latex

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.